Drug-Loaded Hybrid Tissue Engineered Heart Valve with Antithrombosis and Immunomodulation Performance
ACS Applied Materials & Interfaces · 2025
DOI: 10.1021/acsami.4c22022 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2025. Verfasst von Shaoge Bai und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Engineering Research Center for Biomaterials& College of Biomedical Engineering, Sichuan University, Chengdu 610065, China. Hauptthemen laut MEDLINE: Tissue Engineering, Heart Valve Prosthesis, Thrombosis, Curcumin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Chinese Academy of Medical Sciences, National Natural Science Foundation of China.
Abstract (Originalsprache)
High thrombogenicity and shortened lifespan have limited the application of mechanical valves and bioprosthetic valves, respectively. Tissue engineering heart valve (TEHV) holds significant potential as a favorable prosthetic valve to overcome the limitations of the current prosthetic valves, featuring the capabilities of self-pairing and adaptive remodeling. However, TEHVs, mainly fabricated from decellularized xenogeneic heart valves (DHV), still have challenges such as thrombosis, inferior endothelialization, and immune responses. Herein, a drug-loaded glycoprotein-like network hybrid TEHV (OHSC-V) was engineered through the one-pot hybridization of DHV, oxidized HA (OHA), phenylboronic acid grafted silk fibroin (SF-PBA), and curcumin (Cur), where OHA served as a biocompatible backbone to cross-link the DHV and the conjugate of SF-PBA and Cur. With the introduction of the multifunctional drug-loaded glycoprotein-like network, OHSC-V not only effectively inhibited the adsorption of plasma proteins, blood cells, platelets, and thrombosis but also facilitated the endothelialization of TEHV. Furthermore, the OHSC-V eliminated the reactive oxygen species and responsively released Cur to modulate the immune responses. Moreover, the calcification degree of hybrid TEHVs was markedly lower than that of glutaraldehyde cross-linked DHV after 90 days of implantation. Overall, OHSC-V demonstrated enhanced performance of antithrombosis, endothelialization, immunomodulation, and anticalcification, showcasing the further potential for application exploration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Engineering Research Center for Biomaterials& College of Biomedical Engineering, Sichuan University, Chengdu 610065, China.
- Research Unit of Minimally Invasive Treatment of Structural Heart Disease, Chinese Academy of Medical Sciences, No.: 2021RU013, Chengdu 610064, China.
ORCID-Profile: Yunbing Wang
Förderung
- National Key Research and Development Program of China
- Chinese Academy of Medical Sciences
- National Natural Science Foundation of China
Zitieren
APA
Bai, S., Wei, B., Chen, L., Huang, X., Huang, K., Yang, L., Zheng, C., & Wang, Y. (2025). Drug-Loaded Hybrid Tissue Engineered Heart Valve with Antithrombosis and Immunomodulation Performance. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.4c22022
Vancouver
Bai S, Wei B, Chen L, Huang X, Huang K, Yang L, et al. Drug-Loaded Hybrid Tissue Engineered Heart Valve with Antithrombosis and Immunomodulation Performance. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.4c22022
BibTeX
@article{Bai2025,
author = {Bai, Shaoge and Wei, Bangquan and Chen, Lepeng and Huang, Xueyu and Huang, Kaiyang and Yang, Li and Zheng, Cheng and Wang, Yunbing},
title = {Drug-Loaded Hybrid Tissue Engineered Heart Valve with Antithrombosis and Immunomodulation Performance},
journal = {ACS Applied Materials & Interfaces},
year = {2025},
doi = {10.1021/acsami.4c22022}
}
EUVIMED